|Mr. Christopher Michael Cashman||Exec. Chairman, CEO & Pres||613.1k||N/A||1957|
|Mr. Edward F. Smith||CFO, VP, Treasurer & Sec.||433.5k||N/A||1971|
|Dr. Lorianne K. Masuoka||Chief Medical Officer||N/A||N/A||1961|
|Ms. Lisa M. Caperelli||Exec. Director of Investor & Strategic Relations||N/A||N/A||N/A|
|Dr. Kimberly A. McCormick||Head of Regulatory Affairs||N/A||N/A||N/A|
Marinus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three different dose forms: intravenous (IV), capsule, and liquid. The multiple dose forms are intense to maximize the therapeutic range of ganaxolone for adults and pediatric patients. Ganaxolone acts as an anti-seizure, anti-anxiety, and anti-depressive actions; and acts on synaptic and extra synaptic GABAA receptors. The company is also developing ganaxolone for pediatric refractory epilepsy; postpartum depression; and acute epilepsy, which are in Phase II clinical study. In addition, it is developing ganaxolone IV formulation to treat status epilepticus. Marinus Pharmaceuticals, Inc. has a collaboration agreement with NovaMedica, LLC; and license agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc. The company was founded in 2003 and is based in Radnor, Pennsylvania.
Marinus Pharmaceuticals, Inc.’s ISS Governance QualityScore as of October 1, 2018 is 6. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 5; Compensation: 9.